Shape Memory Medical has secured $10 million through a convertible note financing led by new investor August Global Partners and joined by Taiwania Capital. The California-based medical device company develops endovascular embolization therapies using proprietary shape memory polymer technology, with its platform already used across several vascular applications. The new capital will support continued clinical development of its aortic portfolio, including patient follow-up and data collection in the AAA-SHAPE Pivotal Trial and advancement of the FLAGSHIP feasibility study.
Financing Supports Clinical Development
The financing comes as Shape Memory Medical reaches important milestones across its aortic clinical programs, including the recent completion of enrollment in AAA-SHAPE. The company is also backed by healthcare investors including HBM Healthcare Investments, Earlybird Venture Capital, and WexMed II, while Heal Venture Lab supported the latest transaction. President and CEO Ted Ruppel said the funding strengthens the company’s position as it works to generate clinical evidence that could support broader adoption of its polymer technology in aortic procedures.
AAA-SHAPE Pivotal Trial
The AAA-SHAPE Pivotal Trial is evaluating the IMPEDE-FX RapidFill device when used alongside endovascular aneurysm repair, commonly known as EVAR, in patients with abdominal aortic aneurysms. The randomized, multicenter study is examining whether proactive management of the aneurysm sac using Shape Memory Medical’s embolization technology can improve outcomes compared with stand-alone EVAR, with enrolled patients expected to be followed for five years. Completion of enrollment allows the company to shift its focus toward follow-up, data collection, and analysis as it seeks evidence supporting the technology’s safety and effectiveness in this indication.
FLAGSHIP Expands Aortic Focus
Shape Memory Medical is also advancing FLAGSHIP, a first-in-human clinical study evaluating its investigational False Lumen Embolization System for treating aortic dissection. The study is designed to assess safety and preliminary efficacy by targeting the false lumen created when layers of the aortic wall separate, with participants followed for two years. The program expands the company’s strategy beyond aneurysm sac management and explores whether shape memory polymer can provide a purpose-built embolization approach for complex aortic conditions that have historically relied on materials developed for other procedures.
Technology and Investor Support
Shape Memory Medical’s platform uses a low-density, highly porous embolic material that is delivered through a catheter in compressed form and expands after coming into contact with blood. The bioresorbable material is designed to promote organized thrombus formation, conform to complex vascular anatomy, and remain radiolucent to facilitate medical imaging during follow-up, while the company says its products have received approvals in more than 40 countries and have been used in more than 3,500 patients. August Global Partners, a Singapore-based investor focused on healthcare and advanced manufacturing, said it plans to support the company through upcoming clinical milestones and its broader expansion in Asia-Pacific, while Taiwania Capital brings additional international healthcare investment experience.
The $10 million financing provides Shape Memory Medical with additional resources as it moves two major aortic programs through clinical development and longer-term patient assessment. With AAA-SHAPE fully enrolled and FLAGSHIP progressing, the company’s near-term priorities will center on generating evidence that demonstrates whether its shape memory polymer platform can address unmet needs in abdominal aortic aneurysm and aortic dissection treatment. Upcoming clinical results will be critical in determining the technology’s potential for wider adoption, additional regulatory approvals, and broader commercial use in aortic interventions.